Search Results - "Schram, A M"

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies by Barrios, D.M., Phillips, G.S., Geisler, A.N., Trelles, S.R., Markova, A., Noor, S.J., Quigley, E.A., Haliasos, H.C., Moy, A.P., Schram, A.M., Bromberg, J., Funt, S.A., Voss, M.H., Drilon, A., Hellmann, M.D., Comen, E.A., Narala, S., Patel, A.B., Wetzel, M., Jung, J.Y., Leung, D.Y.M., Lacouture, M.E.

“…Immunoglobulin E (IgE) blockade with omalizumab has demonstrated clinical benefit in pruritus-associated dermatoses (e.g. atopic dermatitis, bullous…”
Get full text

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development by Westphalen, C B, Martins-Branco, D, Beal, J R, Cardone, C, Coleman, N, Schram, A M, Halabi, S, Michiels, S, Yap, C, André, F, Bibeau, F, Curigliano, G, Garralda, E, Kummar, S, Kurzrock, R, Limaye, S, Loges, S, Marabelle, A, Marchió, C, Mateo, J, Rodon, J, Spanic, T, Pentheroudakis, G, Subbiah, V

“…Advances in precision oncology led to approval of tumour-agnostic molecularly guided treatment options (MGTOs). The minimum requirements for claiming…”
Get more information

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients by Ross, D.S., Liu, B., Schram, A.M., Razavi, P., Lagana, S.M., Zhang, Y., Scaltriti, M., Bromberg, J.F., Ladanyi, M., Hyman, D.M., Drilon, A., Zehir, A., Benayed, R., Chandarlapaty, S., Hechtman, J.F.

“…Kinase fusions are rare and poorly characterized in breast cancer (BC). We aimed to characterize kinase fusions within a large cohort of advanced BC. A total…”
Get full text

Oncologist use and perception of large panel next-generation tumor sequencing by Schram, A.M., Reales, D., Galle, J., Cambria, R., Durany, R., Feldman, D., Sherman, E., Rosenberg, J., D’Andrea, G., Baxi, S., Janjigian, Y., Tap, W., Dickler, M., Baselga, J., Taylor, B.S., Chakravarty, D., Gao, J., Schultz, N., Solit, D.B., Berger, M.F., Hyman, D.M.

“…Genomic profiling is increasingly incorporated into oncology research and the clinical care of cancer patients. We sought to determine physician perception and…”
Get full text

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors by Borazanci, E., Schram, A.M., Garralda, E., Brana, I., Vieito Villar, M., Spreafico, A., Oliva, M., Lakhani, N.J., Hoffman, K., Hallett, R.M., Maetzel, D., Hua, F., Hilbert, J., Giblin, P., Anido, J., Kelly, A., Vickers, P.J., Wasserman, R., Seoane, J., Siu, L.L., Hyman, D.M., Hoff, D.V., Tabernero, J.

“…Activation of leukemia inhibitory factor (LIF) is linked to an immunosuppressive tumor microenvironment (TME), with a strong association between LIF expression…”
Get full text

685TiPA phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours by Schram, A M, Drilon, A, Mercade, T Macarulla, O’Reilly, E M, Rodon, J A, Wolpin, B M, Ou, S-H I, Kim, D-W, Yang, J C-H, Lam, Y C J, Varga, A, de Langen, A J, Witteveen, P O, Boni, V, Cerea, G, Duruisseaux, M, Liu, S V, Wasserman, E, Hyman, D M, Tabernero, J

“…Abstract Background NRG1 fusions are oncogenic drivers across various cancers. NRG1 fusion proteins bind to HER3, leading to HER2/HER3 heterodimerization,…”
Get full text

Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry by Drilon, Alexander, Duruisseaux, Michael, Han, Ji-Youn, Ito, Masaoki, Falcon, Christina, Yang, Soo-Ryum, Murciano-Goroff, Yonina R, Chen, Haiquan, Okada, Morihito, Molina, Miguel Angel, Wislez, Marie, Brun, Philippe, Dupont, Clarisse, Branden, Eva, Rossi, Giulio, Schrock, Alexa, Ali, Siraj, Gounant, Valérie, Magne, Fanny, Blum, Torsten Gerriet, Schram, Alison M, Monnet, Isabelle, Shih, Jin-Yuan, Sabari, Joshua, Pérol, Maurice, Zhu, Viola W, Nagasaka, Misako, Doebele, Robert, Camidge, D Ross, Arcila, Maria, Ou, Sai-Hong Ignatius, Moro-Sibilot, Denis, Rosell, Rafael, Muscarella, Lucia Anna, Liu, Stephen V, Cadranel, Jacques

“…Although fusions are oncogenic drivers across multiple tumor types including lung cancers, these are difficult to study because of their rarity. The global…”
Get full text